May 23, 2018 / 11:06 AM / 2 months ago

BRIEF-Clementia's Treatment With Palovarotene Significantly Reduces New Bone Growth In Patients With FOP

May 23 (Reuters) - Clementia Pharmaceuticals Inc:

* CLEMENTIA REPORTS POSITIVE PHASE 2 PART B DATA SHOWING TREATMENT WITH PALOVAROTENE SIGNIFICANTLY REDUCES NEW BONE GROWTH IN PATIENTS WITH FOP

* PHASE 2 PART B DATA SHOW EVALUABLE PATIENTS WITH NO NEW BONE AT 12 WEEKS HAD NO NEW BONE AT 12 MONTHS

* STATISTICALLY SIGNIFICANT 91% REDUCTION OF NEW HO AT FLARE-UP SITES AT 12 WEEKS; 65% REDUCTION OF NEW HO AT 12-MONTH WBCT SCAN IN PHASE 2 DATA

* PALOVAROTENE GENERALLY WELL-TOLERATED IN TRIAL, CONSISTENT WITH EXPERIENCE ACROSS PALOVAROTENE CLINICAL STUDIES

* RECENTLY SURPASSED ENROLLMENT OF FIRST 35 PATIENTS IN OUR PHASE 3 MOVE TRIAL, ON TRACK TO COMPLETE STUDY ENROLLMENT BY YEAR END

* ON TRACK TO REPORT FIRST INTERIM ANALYSIS FOR MOVE TRIAL IN MID-2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below